Page 6 March 16, 2017 TORRANCE TRIBUNE Classifieds The deadline for Classified Ad submission and payment is Noon on Tuesday to appear in Thursday’s paper. Advertisements must be submitted in writing by mail, fax or email. You may pay by cash, check, or credit card (Visa or M/C over the phone). Errors: Please check your advertisements immediately. Any corrections and/or changes in an ad must be requested prior to the following Tuesday deadline in order to receive a credit. A credit will be issued for only the first time the error appears. Multiple runs will only be credited for the first time the error appears. No credit will be issued for an amount greater than the cost of the advertisement. Beware: Employment offers that suggest guaranteed out-of-state or overseas positions may be deceptive or unethical in nature. If you have any doubts about the nature of a company, contact the local office of the Better Business Bureau, (213) 251-9696. Herald Publications does not guarantee that the advertiser’s claims are true nor does it take responsibility for those claims. Employment Outside sales: Looking for Outside Sales Representative to sell display ads in Torrance. Sales experience a plus. Work from home, but must call on customers and attend events. Flexible hours, approximately 20 hours a week. $15/hr, plus 10% commission to start, 20% of sales after probation. Interested parties send resume to management@heraldpublications.com. Employment Graphic artist needed: We are looking for a graphic artist to work 20 hours per week. The job entails doing classifieds, DBA notices, ad changes and learning newspaper layout. Must be familiar with Mac computers and work with InDesign, Photoshop, etc. Interested parties please email your resume to management@heraldpublications.com Employment Sales Associate wanted: Sales experience a plus. Sales associates needed for El Segundo, Torrance, Hawthorne. Interested parties email your resume to management@ heraldpublications.com Employment SR. SOFTWARE ENGINEER sought by Onestop Internet, Inc. in El Segundo, CA. Design and develop e-commerce web and internal applications. Send resumes to: Tarin O’Neill, Onestop Internet, Inc., 500 Continental Blvd., Ste. 130, El Segundo, CA 90245. Employment Inside Telephone Sales, Salary Commissions Benefits Leads looking for courageous women and men to earn 6 figures $$$ Call and Email resume to resumes@gettrx.com For Rent 359 Whiting, ES-Back house 3 bd - 2 ba $ 3800 Great westside location, Tree top view, H/W floors, Vault ceilings,Builtins, 2 car garage, sm yard Avail 4/1 S & L Property Mgmt - 310-350-4096 For Rent 413 1/2 Richmond, ES-Back Unit 2 bd-1 ba $2450 Shared garage and Laundry on site.Excellent Location, Pet OK Avail now S & L Property Mgmt - 310-350-4096 For Rent 346 Virginia El Segundo. Private bedroom in house, Full house privileges includes washer/dryer utilities paid, Immaculate. $700/Mo Available March 17th. 310-365-1481 For Rent Free Standing Private Garage – with power, $2,250/MO. 1600 SQ/Ft. Available April 1, 2017. For further information please call Bill Ruane: 310-877-2374 Apartment For Rent 2BD/1BA 220 Arena st. New kitchen, Flooring, Coin laundry, One carport, available early April, 2,100/MO. Jane @ (310)545-2845 Apartment For Rent 3BD/2BTH Small Private Yard, Hardwood Floors, Fridge, Stove, W/D, ½ of Dbl Garage, $2995 (310)433-4562 Help Wanted Help wanted, part time, night auditor at hotel in the LAX area, apply in person. 4501 W Imperial Hwy. (310)671-6017 Services Offered Call Development Oasis today! Enjoy affordable sessions with a Certified Life Coach. Sessions are by appt. only. (310) 956- 8733. 15342 Hawthorne Blvd. Email=developmentoasiscenter@ gmail.com “Helping You Develop The Life You Truly Want to Live.” Visit us online: www.heraldpublications.com Drug Maker from page 3 Robinson reminded the commission staff that the exemption exists so that stockholders of a publicly owned company don’t micromanage how it conducts business. That includes how it sets prices and prepares for any backlash, she wrote. “The supporting statement further requests that the Company provide ‘detailed justification for price increases.’ These mandates demonstrate that the Proposal is seeking to probe deeply into matters of a complex nature upon which stockholders, as a group, are not in a position to make an informed judgment,” Robinson wrote. SEC staff issued its legal opinion in the Amgen matter on February 10 in favor of the drug maker. Though the opinion is nonbinding, the Mercy Investments group will not pursue the issue with Amgen at this year’s shareholder meeting, the group’s attorney said. Identically worded proposals were submitted to at least eight U.S. drug makers, and SEC staff gave a thumbs down to each shareholder plan for more transparency about drug pricing. Mercy Investment members were involved in some, but not all, of the calls for more transparency from the pharmaceutical industry, Nehauser confirmed. It’s possible his client will pursue this issue next year with Amgen management, he said. Other drug makers being pushed by stockholders for more transparency about their pricing decisions include some of the largest pharmaceutical companies in the country. SEC staff in February blocked proposals filed with Biogen, Bristol-Myers, Eli Lilly, Gilead Sciences, Merck & Co., Pfizer and Vertex Pharmaceuticals, according to SEC records. The campaign by faith-based investors, many of them members of an interfaith push for corporate responsibility, doesn’t appear to be finished. The SEC staff’s decision not to recommend any enforcement action against drug makers for ignoring these shareholder requests only covers this year, so they could be back. “The first shareholder proposal on drug pricing that I’m aware of was successful in the 1990s,” Neuhauser said. “There have been successful ones since. I think the problem this year was more the way it worded than the basic notion.” Shareholders in three 2015 cases overcame a drug maker’s resistance to producing its pricing data, according to Neuhauser. In each case, the companies argued like Amgen that investors were trying to micromanage the business operations, yet SEC staff rejected the argument Neuhauser presented in January in writing. The former law school professor pointed to other SEC’s staff opinions regarding drug companies and price-setting. “This is not too intricate a matter for shareholders to understand. Note that it is the rate of increase that is being requested, not the actual prices charged. Indeed, the proposal ‘micromanages’ significantly less than the proposals that were deemed not to micromanage in Celgene Corp. (March 9, 2015), Vertex Pharmaceuticals Inc. (February 25, 2015) and Gilead Sciences, Inc. (February 23, 2015),” he wrote. Calls to Amgen representatives for comment about the pricing of its leading drug therapies went unreturned as of late last week. The company’s website did not mention the SEC lawyer’s favorable ruling. Amgen had product sales of $21.9 billion last year, and total revenues increased six percent, according to 2016 financials. Drug sales grew six percent in 2016 over the previous year, led by a 49 percent increase in sales of Blincyto for leukemia patients. The company’s other big gainers for the year included Kyprolis for treatment of myeloma--up 35 percent--and bone-density-building Prolia, which was up 25 percent in annual sales. The top-10 sellers for Amgen, which the shareholder group targeted in its proposal, generated $16.6 billion for the biotech firm last year. Only a dozen or so drug companies outsell this Southern California success story. The company can choose to address at its annual shareholder meeting the drug-pricing issue and the risks from the current political debate over healthcare costs in the nation’s and state capitals, but for now the federal government watchdog over publicly traded companies won’t force pharmaceutical makers to say anything. This ruling is corporate America’s version of the Miranda rule. The SEC decided a drug maker has the right to remain silent, even when it’s the investorowners of the company asking the questions. •
Torrance_031617_FNL_lorez
To see the actual publication please follow the link above